Skip to main content
Premium Trial:

Request an Annual Quote

NorDiag Extends License to Exact Sciences' Long-DNA Biomarker Tech

NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag. 
 
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
 
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.
 
NorDiag will pay a licensing fee and royalties for the right to use the technology, Exact said. Financial details were not disclosed.
 
Exact Sciences said that when the DIA marker is detected in stool samples, “multiple studies have shown both high sensitivity and specificity for the presence of colorectal cancer.”
 
Exact Sciences CEO Don Hardison said his company looks forward to entering other collaborations with NorDiag “to explore ways in which we may further leverage each other’s strengths, while continuing to advance stool-based DNA testing worldwide.”

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.